Autologous Bone Marrow Transplantation - Blog Science Connections

212 ABMTin Hodgkin's Disease
CR n = 6«
YEARS
(froa time of starting 2nd line therapy
and 6 months)
Figure 3. Survival of patients less than 50 years of age who have failed first-line chemotherapy
according to response to second-line therapy (R/T, radiotherapy; CR, complete
remission; Chemo, chemotherapy).
group of patients who relapsed on MOPP/ABVD (8). The BNLILOPP/EVAP
study has not yet sufficiently progressed to examine those patients whose
treatment with this regimen failed, but these patients may be suitable also for
salvage therapy by ABMT.
Middlesex Hospital Studies
Thirty-two patients with Hodgkin's disease have been treated with intensive
myeloablative therapy (1MT) and ABMT at our center between August
1982 and December 1986. Twenty-nine (22 males and 7 females) were
évaluable post-ABMT. The median age was 29 years, and 76% were between
the ages of 15 and 30 years. Histological findings included nodular sclerosing
(21), mixed cells (7), and lymphocyte predominance (1). No patients had
bone marrow involvement as assessed by study of bilateral iliac crest trephine
biopsy specimens. All patients were in relapse. Two patients (7%) had
primary resistant disease showing relapse through first-line alternating
chemotherapy (LOPP/EVAP [etoposide, vinblastine, Adriamycin, prednisone]).
The remaining 27 patients had undergone at least two regimens of
salvage therapy, including localized radiotherapy in 16 patients (55%). Nine
patients (31 %) were in responding relapse (i.e., were showing partial response
to salvage chemotherapy at the time of ABMT). The remaining 18 patients